This company has been acquired
BELLUS Health Past Earnings Performance
Past criteria checks 0/6
BELLUS Health's earnings have been declining at an average annual rate of -44.7%, while the Biotechs industry saw earnings growing at 32.7% annually. Revenues have been declining at an average rate of 41.4% per year.
Key information
-44.7%
Earnings growth rate
-24.4%
EPS growth rate
| Biotechs Industry Growth | 51.1% |
| Revenue growth rate | -41.4% |
| Return on equity | -23.5% |
| Net Margin | -578,586.7% |
| Last Earnings Update | 31 Mar 2023 |
Recent past performance updates
Recent updates
BELLUS Health (TSE:BLU) Is In A Good Position To Deliver On Growth Plans
Jan 16
Here's Why We're Not Too Worried About BELLUS Health's (TSE:BLU) Cash Burn Situation
Sep 07We're Hopeful That BELLUS Health (TSE:BLU) Will Use Its Cash Wisely
May 05Here's Why We're Watching BELLUS Health's (TSE:BLU) Cash Burn Situation
Jan 06Companies Like BELLUS Health (TSE:BLU) Are In A Position To Invest In Growth
Sep 10Revenue & Expenses BreakdownBeta
How BELLUS Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 23 | 0 | -87 | 21 | 69 |
| 31 Dec 22 | 0 | -76 | 19 | 58 |
| 30 Sep 22 | 0 | -73 | 19 | 53 |
| 30 Jun 22 | 0 | -71 | 17 | 55 |
| 31 Mar 22 | 0 | -70 | 15 | 58 |
| 31 Dec 21 | 0 | -71 | 14 | 59 |
| 30 Sep 21 | 0 | -64 | 13 | 52 |
| 30 Jun 21 | 0 | -47 | 10 | 38 |
| 31 Mar 21 | 0 | -37 | 10 | 29 |
| 31 Dec 20 | 0 | -32 | 10 | 23 |
| 30 Sep 20 | 0 | -34 | 9 | 25 |
| 30 Jun 20 | 0 | -35 | 10 | 25 |
| 31 Mar 20 | 0 | -33 | 8 | 23 |
| 31 Dec 19 | 0 | -26 | 7 | 19 |
| 30 Sep 19 | 0 | -18 | 5 | 14 |
| 30 Jun 19 | 0 | -14 | 4 | 10 |
| 31 Mar 19 | 0 | -9 | 3 | 6 |
| 31 Dec 18 | 0 | -7 | 2 | 5 |
| 30 Sep 18 | 0 | -6 | 3 | 4 |
| 30 Jun 18 | 0 | -5 | 2 | 3 |
| 31 Mar 18 | 0 | -4 | 2 | 3 |
| 31 Dec 17 | 0 | -1 | 2 | 3 |
| 30 Sep 17 | 0 | -1 | 2 | 2 |
| 30 Jun 17 | 1 | 0 | 2 | 1 |
| 31 Mar 17 | 1 | 0 | 2 | 1 |
| 31 Dec 16 | 1 | -2 | 2 | 1 |
| 30 Sep 16 | 3 | -1 | 2 | 1 |
| 30 Jun 16 | 3 | 0 | 2 | 1 |
| 31 Mar 16 | 3 | 0 | 3 | 1 |
| 31 Dec 15 | 3 | 0 | 2 | 1 |
| 30 Sep 15 | 2 | 0 | 2 | 1 |
| 30 Jun 15 | 2 | -1 | 2 | 1 |
| 31 Mar 15 | 2 | -1 | 2 | 1 |
| 31 Dec 14 | 2 | -2 | 3 | 1 |
| 30 Sep 14 | 2 | -2 | 3 | 1 |
| 30 Jun 14 | 2 | -1 | 3 | 1 |
| 31 Mar 14 | 2 | -1 | 4 | 1 |
| 31 Dec 13 | 2 | -1 | 4 | 1 |
| 30 Sep 13 | 2 | -1 | 3 | 1 |
| 30 Jun 13 | 2 | -2 | 3 | 1 |
| 31 Mar 13 | 2 | -10 | 3 | 1 |
| 31 Dec 12 | 2 | -13 | 4 | 1 |
| 30 Sep 12 | 3 | -15 | 5 | 1 |
| 30 Jun 12 | 3 | -14 | 5 | 1 |
Quality Earnings: BLU is currently unprofitable.
Growing Profit Margin: BLU is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BLU is unprofitable, and losses have increased over the past 5 years at a rate of 44.7% per year.
Accelerating Growth: Unable to compare BLU's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BLU is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-25.4%).
Return on Equity
High ROE: BLU has a negative Return on Equity (-23.53%), as it is currently unprofitable.